An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Lycera

Status and phase: Completed; Phase 2

Conditions: Colitis, Ulcerative

Treatments: Drug: LYC-30937-EC; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02762500

2016-000518-31 (EudraCT Number)

LYC-30937-2001

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic score of ≥ 2 and a rectal bleeding score of ≥ 1 at screening.

Full description

Approximately 120 subjects will be randomized to receive either enteric-coated (EC) LYC-30937-EC 25 mg PO once daily (QD) or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-tumor necrosis factor (TNF) agents such that at least 50% of the randomized subjects will be anti-TNF naïve .

The study will consist of 3 phases:

• screening phase: up to 4 weeks
• double-blind placebo-controlled phase treatment: 8 weeks
• post-treatment follow-up: 2 weeks

Eligible subjects will be randomized at Week 0 (Study Day 1) to either LYC-30937-EC 25 mg or placebo. Screening will occur from Study Days -28 to -1. Randomization and first dosing will occur at Week 0/Study Day 1. Double-blind study visits will occur at Weeks 2, 4, and 8, with the last dose at Week 8/Study Day 57. Subjects will return at Week 10 for a post-treatment safety follow-up visit.

Enrollment: 124 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical UC diagnosis ≥ 6 months prior to screening with minimum disease extent of ≥ 15cm from anal verge.
• Active UC defined as a TMS of 4-11 (inclusive) with endoscopic subscore of ≥ 2 and rectal bleeding subscore of ≥ 1 at screening.
• Females of childbearing potential must have a negative pregnancy test at screening and baseline visits and must agree to use acceptable methods of birth control while in the trial and for 30 days after taking the last dose of study drug.
• May be currently receiving treatment with oral aminosalicylates (ASA) for ≥ 6 weeks at a stable dose for ≥ 3 weeks prior to the screening screening endoscopy and/or thiopurine at a stable dose ≥ 8 weeks prior to the screening endoscopy and/or prednisone (dose 20 mg daily) or equivalent for ≥ 4 weeks and receiving stable dose for ≥ 2 weeks prior to screening endoscopy
• able to provide written informed consent and be compliant with study procedures.

Exclusion criteria

• History of Crohn's disease (CD) or indeterminate colitis or the presence or history of fistula consistent with CD.
• Presence of colon polyps.
• Severe extensive disease that in the investigators discretion is likely to require colonic surgery during the 8 week double-blind portion of the trial (eg, fulminant colitis, toxic megacolon, bowel perforation, evidence of acute abdomen).
• History of alcohol or drug abuse within 1 year of randomization.
• History of cancer including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been adequately treated with no recurrence for ≥ 1 year prior to screening.
• History or currently active primary or secondary immunodeficiency.
• Clinically relevant hepatic, neurologic, pulmonary, ophthalmological, gastrointestinal, endocrine, psychiatric, or other major systemic disease making implementation of the study difficult or that would put the subject at risk by participating in the study
• Positive test for Clostridium difficile or positive stool culture for enteric pathogens or presence of ova or parasites at screening.
• Liver function tests > 1.5 x upper limit of normal (ULN) or direct bilirubin > 1.5 x ULN
• Hemoglobin < 8.5 g/dl
• Neutrophils < 1500/mm3
• White blood cell (WBC) count < 3000/mm3
• Platelets < 80000 mm3
• International normalized ratio (INR) > 1.5
• Treatment with an immunosuppressant agent within 8 weeks of screening.
• Previous exposure to ≥ 2 approved or investigational biologic agents to treat UC.
• History of UC treatment with a biologic agent within 12 weeks of screening.
• Treatment with rectal steroids within 2 weeks of screening.
• Treatment with an investigational agent within 30 days of screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

124 participants in 2 patient groups, including a placebo group

LYC-30937-EC 25 mg PO QD

Experimental group

Description:

LYC-30937-EC 25 mg by mouth once daily for 8 weeks

Treatment:

Drug: LYC-30937-EC

Placebo PO QD

Placebo Comparator group

Description:

Matching placebo by mouth once daily for 8 weeks

Treatment:

Drug: Placebo